Listed by the USPTO as MARRISON, SAMUEL JOSEPH
Tech Center 3700 • Art Units: 3783
This examiner grants 68% of resolved cases
MARRISON, SAMUEL JOSEPH examines in tech center 3700 and art unit 3783. The record covers 54 resolved cases, with a 68.5% allowance rate, a 35.7% interview lift, and a 1487-day median time to allowance. The leading companies are The Regents of the University of Michigan, Roche Diabetes Care Inc., and AptarGroup Inc. The leading firms are MARSHALL, GERSTEIN & BORUN LLP, MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, and SUGHRUE MION, PLLC.
The allowance rate indicates that favorable outcomes are available, while the 35.7% interview lift supports active examiner engagement. Practitioners should prepare interviews around specific claim and prior-art issues and preserve the resulting positions in writing. The 1487-day median makes prosecution duration significant for the listed companies and firms, and the 54-case record warrants using the profile as a focused rather than universal guide.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18651068 | DEVICE FOR THE APPLICATION OF A THERAPEUTIC SUBSTANCE IN THE FORM OF A FLUID | Non-Final OA | FUJIFILM CORPORATION |
| 17617837 | REPOSITIONABLE MEDICAL TUBE WITH ULTRASONICALLY-DETECTABLE CUFF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17357715 | VACUUM ASPIRATION SYSTEM FOR TREATING VENOUS THROMBOEMBOLIC DISEASE | Final Rejection | Imperative Care, Inc. |
| 17665042 | MEDICAL DEVICE WITH TACTILE INDICATION | Final Rejection | Roche Diabetes Care, Inc. |
| 18097368 | SAFETY NEEDLE DEVICE | Final Rejection | Becton, Dickinson and Company |
| 17559228 | Methods And Compositions For Using Alternating Electric Fields In Gene Therapy | Non-Final OA | NOVOCURE GMBH |
| 18544200 | SYSTEMS AND METHODS FOR SELECTIVELY ENABLING AND/OR DISABLING FUNCTIONALITY AND/OR SETTINGS IN A SOFTWARE UPDATE IN AN INSULIN PUMP SYSTEM | Final Rejection | Tandem Diabetes Care, Inc. |
| 18288087 | Implantable Device and Therapeutic System with Passive Oxygenation | Final Rejection | Sanofi |
| 18267025 | Electrode System, Electronic System, Drug Delivery Device, and a Method of Manufacturing an Electronic System | Non-Final OA | Sanofi |
| 18143577 | INFUSION SYSTEM AND CATHETER FOR SUCH AN INFUSION SYSTEM | Final Rejection | B. Braun Melsungen AG |
| 17418376 | MEDICAMENT DELIVERY DEVICE | Non-Final OA | SHL MEDICAL AG |
| 17294243 | ACTIVATION PREVENTION CAP ASSEMBLY | Non-Final OA | SHL MEDICAL AG |
| 17822236 | TIME MANAGEMENT FOR TIME-DEPENDENT THERAPY MANAGEMENT SYSTEMS, METHODS, AND DEVICES | Non-Final OA | Bigfoot Biomedical, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy68.5% of resolved applications examined by Samuel Joseph Marrison were allowed (54 resolved cases), compared with 67.2% across Art Unit 3783 over the last five years.
This examiner's interview lift is +35.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Samuel Joseph Marrison took 1,487 days on average from filing to allowance.
Samuel Joseph Marrison examines applications in Art Unit 3783 in Tech Center 3700 (Medical Devices & Mechanical Engineering).